www.rsc.org/chemcomm

ChemComm

Versatile enantiocontrolled synthesis of (+)-fostriecin[†]

Tomoyuki Esumi, Nanako Okamoto and Susumi Hatakeyama*

Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8521, Japan. E-mail: susumi@net.nagasaki-u.ac.jp

Received (in Cambridge, UK) 7th October 2002, Accepted 29th October 2002 First published as an Advance Article on the web 15th November 2002


Fostriecin, a potent protein phosphatase inhibitor and antitumor agent, has been enantioselectively synthesized in naturally occurring form *via* a versatile route, which also allows one to secure all possible stereoisomeres of the C1–C13 fragment including the C11 stereocenter and the geometry of the Δ^{12} -double bond.

Fostriecin (1, CI-920) is a structurally unique phosphate ester produced by Streptomyces pulveraceus.^{1,2} This compound displays potent in vitro activity against various cancerous cell lines (*i.e.* leukemia, lung cancer, breast cancer, ovarian cancer) as well as in vivo antitumor activity.3 However, despite the high potential of fostriecin as an antitumor drug, phase I clinical trails carried out at NCI were halted relatively early due to concerns over the stability and purity of the natural material.⁴ Therefore, an efficient and flexible synthetic route to fostriecin is required for the discovery of analogues that have more desirable physical properties. This situation has spurred much research on the synthesis of fostriecin⁵ and Boger et al.³ have achieved the first synthesis in 2001. Just recently, three groups⁶ also reported successful total synthesis. We now report a novel enantiocontrolled synthesis of fostriecin, which enables us to prepare various analogues as well.


From a retrosynthetic perspective (Scheme 1) we focused on a strategy wherein the phosphate ester and sensitive triene arise from alkenyl iodide 2 late in the synthesis. In order to make our approach flexible, we envisaged ynone 6 as a precursor of 2. We expected that alkenyl iodide 2 as well as its stereoisomers 3, 4 and 5 would each be available from 6 by the combination of stereoselective formation of the *E*- or *Z*- β -iodoenone and 9-OH directed *anti*- or *syn*-selective reduction.


Scheme 2 illustrates the asymmetric synthesis of the key ynone based on asymmetric allylation, ring-closing alkene metathesis,⁷ and Sharpless asymmetric dihydroxylation.⁸

According to Aldisson's procedure,⁹ dihydrofuran was converted to stannane 7 with perfect *E*-selectivity. After *p*-




† Electronic supplementary information (ESI) available: experimental section. See http://www.rsc.org/suppdata/cc/b2/b209742g/ methoxybenzylation of 7, iodination of 8 followed by Heck reaction¹⁰ of **9** with acrolein afforded aldehvde **10**. Brown's asymmetric allylation¹¹ of **10** gave alcohol **11** in good yield. The optical purity of 11 was not determined at this stage because of its instability under conditions of the HPLC analysis using a chiral column or formation of the corresponding MTPA esters. After acryloylation, ring-closing alkene metathesis of 12 was examined under various conditions and it was found that cyclization took place between the two terminal alkenic double bonds with high site selectivity.¹² Thus, upon treatment of 12 with 0.1 equivalents of Grubbs' catalyst in CH2Cl2 at reflux for 22 h, lactone 13 was obtained in 75% yield together with the corresponding dimer in 4% yield. In this particular case, the dimer was the only side-product produced and the conjugated diene moiety did not react at all. The optical purity of 13 was determined to be 77% ee by HPLC using a chiral column, indicating the enantioselectivity of the above-mentioned asymmetric allylation. However, we were pleased to find that Sharpless dihydroxylation of 13 using AD-mix- β produced enantiomerically pure diol 14 in 80% yield. Obviously, the dihydroxylation reaction was accompanied by kinetic resolution and occurred at the most electron-rich and sterically less hindered olefin with perfect regio- and diastereoselectivity.5c,13





10.1039/b209742g

BOI



Scheme 3 *Reagents and conditions*: i, NaI (2 equiv.), AcOH (1 equiv.), acetone, **20** (63%) + **21** (6%); ii, NaI (1.1 equiv.), AcOH (4.4 equiv.), 81%; iii, 47% HF–pyridine–H₂O–MeCN (1:4:2:20), 0 °C, 81%; iv, Me₄NB(OAc)₃H, AcOH, MeCN, -30 °C, 99%; v, NaBH₄, Et₃B, MeOH–THF, -78 °C, then 30% H₂O₂, NaHCO₃, 90%; vi, *t*-BuMe₂SiOTf, 2,6-lutidine, CH₂Cl₂, -78 °C, 88%; vii, **28**, Pd(MeCN)₂Cl₂ (2.5 mol%), DMF, 0 °C, 88%; viii (H₂C=CHCH₂O)₂PN(*i*-Pr)₂, tetrazole, CH₂Cl₂, 0 °C, then *t*-BuO₂H, 0 °C, 89%; ix, Pd(PPh₃)₄ (10 mol%), HCO₂NH₂, PPh₃, THF, then Dowex-50 (H⁺ form), MeOH; x, 47% HF–pyridine–H₂O–MeCN (1:4:2:20), then NaHCO₃, 79% from **30**.

Diol 14 was then converted to ynone 19 *via* addition of acetylene to aldehyde 17 in 84% overall yield *via* a five-step sequence.

According to Kishi's methodology,14 19 was exposed to 1.1 equivalents of NaI and 4.4 equivalents of acetic acid without solvent at room temperature. In this case, even after 30 min, the kinetically formed Z-isomer 20 isomerized to the thermodynamically more stable *E*-isomer **21** to an appreciable extent (Z: E = 76: 24) and after 3 h pure **21** was obtained in 81% yield. After experimentation under various conditions using solvent to retard the isomerization, we eventually found that acetone was the solvent of choice for the predominant production of Zisomer 20. Thus, treatment of 19 with 2 equivalents of NaI and 1 equivalent of acetic acid in acetone at room temperature gave a chromatographically separable 91:9 mixture of 20 and 21 in 69% yield. From Z-isomer 20 either the 11R- or 11Sstereocenter was established selectively via 22 by two methods. After selective desilylation of 20, Evans' anti-selective reduction¹⁵ of 22 using Me₄NB(OAc)₃H resulted in formation of 11R-diol 23 with 84% de in quantitative yield. On the other hand, NaBH₄ reduction using triethylborane¹⁶ converted 22 to 11S-diol 24 with perfect selectivity in good yield. Similarly, from E-isomer 21 the corresponding 11R-diol 25 and 11S-diol 26 were obtained with perfect selectivity, respectively (Scheme 3)

Having developed the methodology to attain 23 and all of its isomers including the C11 stereocenter and the geometry of the Δ^{12} -double bond, we then investigated the conversion of 23 to fostriecin. Selective silvlation of 23 afforded Jacobsen's intermediate 27^{6a} which was then subjected to palladium-catalyzed Stille coupling¹⁷ with stannane 28,¹⁸[‡] to produce 29 with perfect stereoselectivity. It should be highlighted that the final phosphorylation-deprotection step employed in the previous syntheses^{3,6} was highly improved by use of a diallyl phosphoryl group in place of a di-p-methoxybenzyl phosphoryl group. Thus, reaction of 29 with diallyl diisopropylaminophosphine¹⁹ followed by treatment of the resulting phosphite with tert-butyl hydroperoxide gave 30 in good yield. Finally, palladium-catalyzed reductive deallylation²⁰ of **30** followed by desilylation of 31 using HF-pyridine cleanly furnished (+)-fostriecin (1). The synthetic substance was identical with natural fostriecin ($[\alpha]_D$, ¹H and ¹³C NMR, FAB–MS, IR, UV and HPLC).

In conclusion, we have accomplished a total synthesis of (+)-fostriecin from dihydrofuran in 21 steps in 4.5% overall yield. This synthesis provides a flexible route to fostriecin analogues required for biological testing.

We thank Dr R. Schultz of the Drug Synthesis and Chemistry Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute for a sample of natural fostriecin. Partial financial support from the Ministry of Education, Science, Sports and Culture of Japan is gratefully acknowledged.

Notes and references

[‡] Prepared from propargyl alcohol in 67% overall yield: i, propargyl alcohol, LiAlH₄, THF, 0 °C then Bu₃SnOTf, rt; ii, (COCl)₂, DMSO, CH₂Cl₂, -78 °C then Et₃N, Ph₃P=CHCO₂Et, rt; iii, *i*-Bu₂AlH, CH₂Cl₂, -78 °C; iv, *t*-BuPh₂SiCl, DMAP-Et₃N, CH₂Cl₂, 0 °C. For step i: E. J. Corey and T. M. Eckrich, *Tetrahedron Lett.*, 1984, **25**, 2419.

- J. B. Tunac, B. D. Graham and W. E. Dobson, J. Antibiot., 1983, 36, 1595; S. S. Stampwala, R. H. Bunge, T. R. Hurley, N. E. Willmer, A. J. Brankiewicz, C. E. Steinman, T. A. Smitka and C. French, J. Antibiot., 1983, 36, 1601.
- 2 Complete stereochemical assignment: D. L. Boger, M. Hikota and B. M. Lewis, J. Org. Chem., 1997, 62, 1748.
- 3 The first synthesis and biological backgrounds: D. L. Boger, S. Ichikawa and W. Zhong, *J. Am. Chem. Soc.*, 2001, **123**, 4161 and references therein.
- 4 R. S. De Jung, N. H. Mulder, D. R. A. Uges, D. Th. Sleijfer, F. J. P. Hoppener, H. J. M. Groen, P. H. B. Willemse, W. T. A. Van der Graaf and E. G. E. De Vries, *Br. J. Cancer*, 1999, **79**, 882.
- 5 Synthetic studies: (a) G. Just and B. O'Connor, *Tetrahedron Lett.*, 1988, 29, 753; (b) J. Cossy, F. Pradaux and S. BouzBouz, *Org. Lett.*, 2001, 3, 2233; (c) Y. Kiyotsuka, J. Igarashi and Y. Kobayashi, *Tetrahedron Lett.*, 2002, 43, 2725.
- 6 (a) D. E. Chavez and E. N. Jacobsen, Angew. Chem., Int. Ed., 2001, 40, 3667; (b) Y. K. Reddy and J. R. Falck, Org. Lett., 2002, 4, 969; (c) K. Miyashita, M. Ikejiri, H. Kawasaki, S. Maemura and T. Imanishi, Chem. Commun., 2002, 742.
- 7 Review: R. H. Grubbs and S. Chang, Tetrahedron, 1998, 54, 4413.
- 8 Review: H. C. Kolb, M. S. VanNieuwenhze and K. B. Sharpless, *Chem. Rev.*, 1994, 94, 2483.
- 9 V. Fargeas, P. L. Ménez, I. Berque, J. Aldisson and A. Panctazi, *Tetrahedron*, 1996, **52**, 6613.
- 10 T. Jeffry, Tetrahedron Lett., 1985, 26, 2667.
- 11 P. K. Jadav, K. S. Bhat, P. T. Perumal and H. C. Brown, J. Org. Chem., 1986, 51, 432.
- 12 Related ring closing alkene metathesis giving α,β-unsaturated δlactones: P. V. Ramachandran, M. V. R. Reddy and H. C. Brown, *Tetrahedron Lett.*, 2000, **41**, 583; Y. Du and D. F. Wimer, *Tetrahedron Lett.*, 2001, **41**, 6069; see also ref. 5(b) and 6(c).
- 13 H. Becker, M. A. Soler and K. B. Sharpless, *Tetrahedron*, 1995, 51, 1345.
- 14 M. Taniguchi, S. Kobayashi, M. Nakagawa, T. Hino and Y. Kishi, *Tetrahedron Lett.*, 1986, 27, 4763.
- 15 D. A. Evans, T. Chapman and E. M. Carreira, J. Am. Chem. Soc., 1988, 110, 3560.
- 16 K.-M. Chen, E. Hardtmann, K. Prasad, O. Repic and M. J. Shapiro, *Tetrahedron Lett.*, 1987, 28, 155.
- 17 J. K. Stille and B. L. Groh, J. Am. Chem. Soc., 1987, 109, 813.
- 18 A. K. Mapp and C. H. Heathcock, J. Org. Chem., 1999, 64, 23.
- 19 W. Bannwarth and A. Trzeciak, Helv. Chim. Acta, 1987, 70, 175.
- 20 I. Minami, Y. Ohashi, I. Shimizu and J. Tsuji, *Tetrahedron Lett.*, 1985, 26, 2449; Y. Hayakawa, S. Wakabayashi, T. Nobori and R. Noyori, *Tetrahedron Lett.*, 1987, 28, 2259.